CJC-1295 research guide for Elexalde. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Research-Grade CJC-1295 for Elexalde Investigators
CJC-1295 isn't available on pharmacy shelves in Elexalde or virtually any local market — it's a research compound supplied via a dedicated online market. This online-only market structure is a genuine benefit for researchers — top vendors differentiate through analytical documentation in ways brick-and-mortar outlets simply cannot. Separating genuine research-grade CJC-1295 from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Elexalde researchers the framework to verify sourcing options methodically and source research-grade CJC-1295 with confidence.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Elexalde researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
Vetting CJC-1295 vendors requires starting from the COA: locate the batch-specific certificate prior to buying, not after. The HPLC purity trace is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be at or above 98%. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that omit endotoxin testing. The dry lyophilised powder of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Elexalde
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bac water. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. The research literature on CJC-1295 should be read critically before designing any protocol — study methodologies, dosing, and endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
